PUMA BIOTECHNOLOGY

Company snapshot

At Puma Biotechnology, our focus is on bringing innovative therapies to patients to enhance cancer care. We are thankful to be part of the HER2+ breast cancer community and are passionate about evaluating options that may benefit patients across the breast cancer therapy spectrum.

• 1 approved product(s) across US/EU regulatory metadata.
• 40 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for PUMA BIOTECHNOLOGY. Not investment advice.

• trial_data Jun 7, 2026

  Puma Biotechnology Inducement Awards: Strategic Talent Moves Under Nasdaq Rule 5635(c)(4)

• Peer + 0 momentum

  BEONE MEDICINES AUS

  TA overlap score 40

• Peer + 0 momentum

  Novartis India

  TA overlap score 40

• Peer + 0 momentum

  Pfizer

  TA overlap score 39.6

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 32.4

• Peer + 0 momentum

  Sun Yat-sen Memorial

  TA overlap score 31.4

• Peer + 0 momentum

  Prelude Therapeutics

  TA overlap score 22.6

• Peer + 0 momentum

  ATOSSA THERAPEUTICS

  TA overlap score 22

• Peer + 0 momentum

  INTENSITY THERAPEUTICS

  TA overlap score 21.2

Recent activity

Latest pipeline, patent, and corporate events for PUMA BIOTECHNOLOGY.

1. Jun 8, 2026 Clinical update

   PUMA-ALI-1201 — Phase 2

2. Jun 8, 2026 Clinical update

   Temsirolimus — Phase 2

3. Jun 8, 2026 Clinical update

   Osimertinib — Phase 1

4. Jun 8, 2026 Clinical update

   neratinib — Phase 1

5. Jun 8, 2026 Clinical update

   Neratinib — Phase 2

View all clinical trial activity →

• What is PUMA BIOTECHNOLOGY?

  Puma Biotechnology is a biotech organization headquartered in Los Angeles, USA. It trades on NYSE under ticker PBYI. Primary therapeutic focus areas include Breast Cancer, Advanced Breast Cancer, HER2+ Metastatic Breast Cancer (MBC), Hormone Receptor Positive HER-2 Negative Breas

• Is PUMA BIOTECHNOLOGY publicly traded?

  Yes. PUMA BIOTECHNOLOGY is listed with ticker PBYI on NYSE per SEC EDGAR records linked on this profile.

• What drugs does PUMA BIOTECHNOLOGY develop or market?

  We link 23 drug profile(s) where PUMA BIOTECHNOLOGY is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/puma-biotechnology-inc#company-drugs.

• What are the latest developments for PUMA BIOTECHNOLOGY?

  In the last 12 months our linked public records show 40 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does PUMA BIOTECHNOLOGY focus on?

  PUMA BIOTECHNOLOGY focuses on Breast Cancer, Advanced Breast Cancer, HER2+ Metastatic Breast Cancer (MBC) based on our analysis of their pipeline programs and drug development activities.